Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Products under Development by Stage of Development | 7 | 1 |
| Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Products under Development by Therapy Area | 8 | 1 |
| Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Products under Development by Indication | 9 | 1 |
| Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Products under Development by Companies | 12 | 2 |
| Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Therapeutics Assessment | 14 | 5 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 1 |
| Assessment by Route of Administration | 16 | 2 |
| Assessment by Molecule Type | 18 | 1 |
| Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Companies Involved in Therapeutics Development | 19 | 3 |
| Celtaxsys, Inc. | 19 | 1 |
| Johnson &Johnson | 20 | 1 |
| Nippon Kayaku Co., Ltd. | 21 | 1 |
| Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Drug Profiles | 22 | 10 |
| acebilustat Drug Profile | 22 | 3 |
| CTX-3397 Drug Profile | 25 | 1 |
| CTX-3421 Drug Profile | 26 | 1 |
| EDO-66 Drug Profile | 27 | 1 |
| JNJ-26993135 Drug Profile | 28 | 1 |
| Small Molecules to Inhibit Leukotriene B4 for Chronic Obstructive Pulmonary Disease Drug Profile | 29 | 1 |
| ubenimex Drug Profile | 30 | 2 |
| Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Dormant Projects | 32 | 1 |
| Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) Featured News &Press Releases | 33 | 9 |
| Jul 25, 2016: Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema | 33 | 1 |
| Jul 18, 2016: Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension | 33 | 1 |
| May 03, 2016: Celtaxsys Begins EU Enrollment for CF Lung Function Preservation Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis | 34 | 1 |
| Mar 28, 2016: Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation for Ubenimex in Pulmonary Arterial Hypertension by European Medicines Agency | 35 | 1 |
| Dec 15, 2015: Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering Bestatin (Ubenimex) for the Treatment of Pulmonary Arterial Hypertension | 35 | 1 |
| Nov 30, 2015: Eiger BioPharmaceuticals Granted Orphan Drug Status for Ubenimex in Pulmonary | 35 | 1 |
| Oct 08, 2015: Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis | 36 | 1 |
| Oct 01, 2015: Celtaxsys to Present Clinical Data on Oral Acebilustat at North American Cystic Fibrosis Conference: Key Inflammation Biomarkers Reduced in CF Patients | 36 | 1 |
| Jul 06, 2015: Celtaxsys Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis | 37 | 1 |
| Jun 10, 2015: Celtaxsys Presents Clinical Data on Oral CTX-4430 at 2015 European Cystic Fibrosis Conference: Positive Impacts on Key Biomarkers in Patients with CF | 38 | 1 |
| Jun 02, 2015: Celtaxsys Receives $5M Research Award to Advance Once Daily, Oral Anti-Inflammatory Medicine into Phase 2 CF Patient Lung Function Preservation Trial | 38 | 1 |
| Apr 07, 2015: Celtaxsys Has Regulatory Clearance to Begin Phase 2 Trial of Oral CTX-4430 Anti-Inflammatory Therapy for Moderate to Severe Acne Vulgaris - Recruitment of Patients to Commence Immediately | 39 | 1 |
| Feb 03, 2015: Celtaxsys Lead Candidate Granted Orphan Designation in Cystic Fibrosis by FDA | 40 | 1 |
| Oct 30, 2014: Celtaxsys Cystic Fibrosis Therapy Receives Positive Opinion In EU | 40 | 1 |
| Oct 10, 2013: Celtaxsys Initiates First Clinical Trial of Oral CTX-4430 Therapy in Cystic Fibrosis Patients | 41 | 1 |
| Appendix | 42 | 2 |
| Methodology | 42 | 1 |
| Coverage | 42 | 1 |
| Secondary Research | 42 | 1 |
| Primary Research | 42 | 1 |
| Expert Panel Validation | 42 | 1 |
| Contact Us | 42 | 1 |
| Disclaimer | 43 | 1 |